A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie zaawansowanego raka nerki, który nie może być operacyjnie usunięty lub wyleczony promieniowaniem
- •Osoba wcześniej nie przyjmowała systemowego leczenia (chemioterapii) na etapie przerzutów
- •Widoczne na badaniach imaging zmiany nowotworowe do zmierzenia
- •Może mieć wcześniejsze leczenie przed operacją lub po operacji usunięcia guza, ale nie lekami działającymi na naczynia krwionośne
✗ Disqualifies
- •Przerzuty do mózgu, które nie były leczone
- •Stosowanie kortykosteroidów (powyżej 10 mg dziennie) lub leków osłabiających odporność w ciągu 14 dni przed началem badania
- •Historia choroby płuc związanej z zapaleniem tkanki
- •Niekontrolowany wyciek płynu w osierdziu lub opłucnej wymagający powtarzanych procedur drażnienia
- •Poważne choroby serca, takie jak zawał, niestabilna dławica piersiowa lub skrzeplina w tętnicy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (91)
Local Institution - 0178
Palo Alto, United States
Local Institution - 0117
New Haven, United States
Sibley Memorial Hospital
Washington D.C., United States
Local Institution - 0177
Miami, United States
Local Institution - 0126
Orlando, United States
Local Institution - 0175
Atlanta, United States
Local Institution - 0170
Fort Wayne, United States
Local Institution - 0124
Iowa City, United States
Johns Hopkins Hospital
Baltimore, United States
Local Institution - 0176
Big Rapids, United States
Washington University School of Medicine
St Louis, United States
Memorial Sloan Kettering Cancer Center
Hauppauge, United States
Local Institution - 0135
Cincinnati, United States
Cleveland Clinic
Cleveland, United States
MUSC Hollings Cancer Center
Charleston, United States
Carolina Urologic Research Center, LLC
Myrtle Beach, United States
Local Institution - 0158
Salt Lake City, United States
Local Institution - 0095
Seattle, United States
Local Institution - 0154
Buenos Aires, Argentina
Local Institution - 0156
Buenos Aires, Argentina
Macquarie University
North Ryde, Australia
GenesisCare St Leonards
St Leonards, Australia
Local Institution - 0011
Herston, Australia
Local Institution - 0074
South Brisbane, Australia
Local Institution - 0003
Malvern, Australia
Hospital Sirio Libanes
Brasília, Brazil
Local Institution - 0007
Calgary, Canada
Local Institution - 0109
Montreal, Canada
Local Institution - 0009
Montreal, Canada
Local Institution - 0105
Santiago, Chile
Bradfordhill
Santiago, Chile
Local Institution - 0163
Santiago, Chile
Local Institution - 0143
Beijing, China
Local Institution - 0157
Beijing, China
Local Institution - 0182
Guangzhou, China
Local Institution - 0183
Changsha Shi, China
Local Institution - 0184
Nanjing, China
Local Institution - 0188
Shanghai Shi, China
Local Institution - 0144
Beijing, China
Local Institution - 0052
Cali, Colombia
Local Institution - 0147
Prague, Czechia
Local Institution - 0149
Brno, Czechia
Local Institution - 0150
Hradec Králové, Czechia
Local Institution - 0044
Helsinki, Finland
Local Institution - 0029
Turku, Finland
Local Institution - 0060
Vantaa, Finland
Local Institution - 0083
Lille, France
Local Institution - 0080
Boredeaux, France
Local Institution - 0028
Villejuif, France
Local Institution - 0025
Jena, Germany
Local Institution - 0026
Hamburg, Germany
Local Institution - 0014
Herne, Germany
Local Institution - 0027
München, Germany
Local Institution - 0059
Dublin, Ireland
Local Institution - 0062
Dublin, Ireland
Local Institution - 0139
Verona, Italy
Local Institution - 0073
Milan, Italy
Local Institution - 0087
Napoli Campania, Italy
Local Institution - 0180
Kobe, Japan
Local Institution - 0179
Shiwa-gun Yahaba-cho, Japan
The Cancer Institute Hospital of JFCR
Koto-ku, Japan
Local Institution - 0078
Toyoma, Japan
Kyushu University Hospital
Fukuoka, Japan
Local Institution - 0181
Niigata, Japan
Local Institution - 0046
Monterrey, Mexico
Local Institution - 0048
Oaxaca City, Mexico
Local Institution - 0122
Puebla City, Mexico
Local Institution - 0049
Tlalpan, Mexico
Local Institution - 0108
Tlalpan, Mexico
Local Institution - 0118
Tlalpan, Mexico
Local Institution - 0103
Cluj-Napoca, Romania
Local Institution - 0161
Craiova, Romania
Local Institution - 0100
Iași, Romania
Local Institution - 0101
Sibiu, Romania
Local Institution - 0112
Seoul, South Korea
Local Institution - 0017
Seoul, South Korea
Local Institution - 0167
Seoul, South Korea
Local Institution - 0013
Madrid, Spain
Local Institution - 0091
Madrid, Spain
Local Institution - 0043
Seville, Spain
Kantonsspital Graubünden
Chur, Switzerland
HOCH Health Ostschweiz
Sankt Gallen, Switzerland
UniversitätsSpital Zürich
Zurich, Switzerland
Royal Marsden Hospital (Chelsea)
London, United Kingdom
St Bartholomew's Hospital
London, United Kingdom
Local Institution - 0186
Preston, United Kingdom
Local Institution - 0022
Cambridge, United Kingdom
Velindre Cancer Centre
Cardiff, United Kingdom
Local Institution - 0061
Edinburgh, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Royal Marsden Hospital Sutton
Sulton, Surrey, United Kingdom
Trial contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
First line of the email MUST contain NCT # and Site #.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.